Standard

Different shades of pancreatic ductal adenocarcinoma, different paths towards precision therapeutic applications. / Martens, Sandrina; Lefesvre, Pierre; Nicolle, Rémy; Biankin, Andrew V.; Puleo, Francesco; Van Laethem, Jean-Luc; Rooman, Ilse.

In: Annals of Oncology, Vol. 30, No. 9, 09.2019, p. 1428-1436.

Research output: Contribution to journalArticleResearchpeer-review

Harvard

APA

Vancouver

Author

Martens, Sandrina ; Lefesvre, Pierre ; Nicolle, Rémy ; Biankin, Andrew V. ; Puleo, Francesco ; Van Laethem, Jean-Luc ; Rooman, Ilse. / Different shades of pancreatic ductal adenocarcinoma, different paths towards precision therapeutic applications. In: Annals of Oncology. 2019 ; Vol. 30, No. 9. pp. 1428-1436.

BibTeX

@article{e98db25c68eb4a25bf71c2f4d9bafb3b,
title = "Different shades of pancreatic ductal adenocarcinoma, different paths towards precision therapeutic applications",
abstract = "Background: Different histological and molecular subtypes of pancreatic ductal adenocarcinoma (PDAC), with different molecular composition and survival statistics, have recently been recognised. Materials and methods: This review describes the currently available studies regarding molecular and histological subtypes in PDAC. Studies from major cohorts such as International Cancer Genome Consortium as well as smaller cohorts are reviewed. We discuss where the described subtypes overlap, where the discrepancies are and which paths forward could be taken regarding diagnosis, ontogeny and therapy. Results: Four molecular subtypes with strong overlap among the different studies can be found, next to a list of mixed findings. Two of the four subtypes (epithelial classical and mesenchymal basal-like) were represented in every study and were often discriminated in other solid tumours as well. These two subtypes differ substantially in prognosis. One biomarker has been discovered, only discriminating these two subtypes, and insights into subtype-specific therapeutic vulnerabilities are scarce. Conclusion: Subtypes can be reproducibly detected in cohorts of PDAC patients and two of them directly relate with prognosis. A consensus on the subtypes is warranted. Further discovery and validation studies are needed to identify strong biomarkers, to comprehend subtype ontogeny and to define strategies for precision medicine.",
keywords = "cancer, histopathology, pancreatic ductal adenocarcinoma, subtyping, transcriptomics",
author = "Sandrina Martens and Pierre Lefesvre and R{\'e}my Nicolle and Biankin, {Andrew V.} and Francesco Puleo and {Van Laethem}, Jean-Luc and Ilse Rooman",
year = "2019",
month = "9",
doi = "10.1093/annonc/mdz181",
language = "English",
volume = "30",
pages = "1428--1436",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "9",

}

RIS

TY - JOUR

T1 - Different shades of pancreatic ductal adenocarcinoma, different paths towards precision therapeutic applications

AU - Martens, Sandrina

AU - Lefesvre, Pierre

AU - Nicolle, Rémy

AU - Biankin, Andrew V.

AU - Puleo, Francesco

AU - Van Laethem, Jean-Luc

AU - Rooman, Ilse

PY - 2019/9

Y1 - 2019/9

N2 - Background: Different histological and molecular subtypes of pancreatic ductal adenocarcinoma (PDAC), with different molecular composition and survival statistics, have recently been recognised. Materials and methods: This review describes the currently available studies regarding molecular and histological subtypes in PDAC. Studies from major cohorts such as International Cancer Genome Consortium as well as smaller cohorts are reviewed. We discuss where the described subtypes overlap, where the discrepancies are and which paths forward could be taken regarding diagnosis, ontogeny and therapy. Results: Four molecular subtypes with strong overlap among the different studies can be found, next to a list of mixed findings. Two of the four subtypes (epithelial classical and mesenchymal basal-like) were represented in every study and were often discriminated in other solid tumours as well. These two subtypes differ substantially in prognosis. One biomarker has been discovered, only discriminating these two subtypes, and insights into subtype-specific therapeutic vulnerabilities are scarce. Conclusion: Subtypes can be reproducibly detected in cohorts of PDAC patients and two of them directly relate with prognosis. A consensus on the subtypes is warranted. Further discovery and validation studies are needed to identify strong biomarkers, to comprehend subtype ontogeny and to define strategies for precision medicine.

AB - Background: Different histological and molecular subtypes of pancreatic ductal adenocarcinoma (PDAC), with different molecular composition and survival statistics, have recently been recognised. Materials and methods: This review describes the currently available studies regarding molecular and histological subtypes in PDAC. Studies from major cohorts such as International Cancer Genome Consortium as well as smaller cohorts are reviewed. We discuss where the described subtypes overlap, where the discrepancies are and which paths forward could be taken regarding diagnosis, ontogeny and therapy. Results: Four molecular subtypes with strong overlap among the different studies can be found, next to a list of mixed findings. Two of the four subtypes (epithelial classical and mesenchymal basal-like) were represented in every study and were often discriminated in other solid tumours as well. These two subtypes differ substantially in prognosis. One biomarker has been discovered, only discriminating these two subtypes, and insights into subtype-specific therapeutic vulnerabilities are scarce. Conclusion: Subtypes can be reproducibly detected in cohorts of PDAC patients and two of them directly relate with prognosis. A consensus on the subtypes is warranted. Further discovery and validation studies are needed to identify strong biomarkers, to comprehend subtype ontogeny and to define strategies for precision medicine.

KW - cancer

KW - histopathology

KW - pancreatic ductal adenocarcinoma

KW - subtyping

KW - transcriptomics

UR - http://www.scopus.com/inward/record.url?scp=85072747064&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdz181

DO - 10.1093/annonc/mdz181

M3 - Article

VL - 30

SP - 1428

EP - 1436

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 9

ER -

ID: 47093490